These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16779730)

  • 1. Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization.
    Vu DM; Kelly D; Heath PT; McCarthy ND; Pollard AJ; Granoff DM
    J Infect Dis; 2006 Jul; 194(2):231-7. PubMed ID: 16779730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
    Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
    Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.
    Vu DM; Welsch JA; Zuno-Mitchell P; Dela Cruz JV; Granoff DM
    J Infect Dis; 2006 Mar; 193(6):821-8. PubMed ID: 16479517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for Rise in Meningococcal Serogroup C Bactericidal Antibody Titers in the Absence of Booster Vaccination in Previously Vaccinated Children.
    Badahdah AM; Khatami A; Tashani M; Rashid H; Booy R
    Pediatr Infect Dis J; 2018 Mar; 37(3):e66-e71. PubMed ID: 29227467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.
    Harris SL; King WJ; Ferris W; Granoff DM
    Infect Immun; 2003 Jan; 71(1):275-86. PubMed ID: 12496177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
    Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine.
    Granoff DM; Morgan A; Welsch JA
    Pediatr Infect Dis J; 2005 Feb; 24(2):132-6. PubMed ID: 15702041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
    Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
    Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine.
    Granoff DM; Harris SL
    Pediatr Infect Dis J; 2004 Jun; 23(6):490-7. PubMed ID: 15194828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of meningococcal serogroup C vaccine programmes.
    Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
    Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.
    Harris SL; Finn A; Granoff DM
    Infect Immun; 2003 Jun; 71(6):3402-8. PubMed ID: 12761124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.
    Badahdah AM; Rashid H; Khatami A
    Expert Rev Vaccines; 2016; 15(1):9-29. PubMed ID: 26560735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.
    Trotter CL; Borrow R; Findlow J; Holland A; Frankland S; Andrews NJ; Miller E
    Clin Vaccine Immunol; 2008 Nov; 15(11):1694-8. PubMed ID: 18827191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison on the levels of human serum antibody against Neisseria meningitidis serogroup C measured using serum bactericidal assay and ELISA].
    Zhu BQ; Xu L; Zhou HJ; Shao ZJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 May; 33(5):521-4. PubMed ID: 22883183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of conjugate meningococcus C vaccine in pediatric solid organ transplant recipients.
    Zlamy M; Elias J; Vogel U; Frosch M; Jeller V; Cortina G; Jungraithmayr T; Prelog M
    Vaccine; 2011 Aug; 29(37):6163-6. PubMed ID: 21718742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.
    Snape MD; Kelly DF; Lewis S; Banner C; Kibwana L; Moore CE; Diggle L; John T; Yu LM; Borrow R; Borkowski A; Nau C; Pollard AJ
    BMJ; 2008 Jun; 336(7659):1487-91. PubMed ID: 18535032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.
    Ladhani SN; Giuliani MM; Biolchi A; Pizza M; Beebeejaun K; Lucidarme J; Findlow J; Ramsay ME; Borrow R
    Emerg Infect Dis; 2016 Feb; 22(2):309-11. PubMed ID: 26811872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.
    Bettinger JA; Scheifele DW; Halperin SA; Kellner JD; Vanderkooi OG; Schryvers A; De Serres G; Alcantara J
    Vaccine; 2012 Jun; 30(27):4023-7. PubMed ID: 22537988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.